ClinicalTrials.gg
CompletedNCT01532648Updated Sep 6, 2019Results posted

Randomized Placebo-Controlled Trial of Budesonide Multi-Matrix System (MMX®) 9 Milligrams (mg) in Participants With Ulcerative Colitis Currently on a 5-Aminosalicylic Acid (5-ASA)

A Phase 3 interventional study of Budesonide MMX® and Placebo in Ulcerative Colitis, sponsored by Bausch Health Americas, Inc.. Completed at 114 sites in 11 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-09-06.

Sponsored by Bausch Health Americas, Inc. (part of Bausch Health Companies Inc.) · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
510
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 10 studies testing budesonide in Colitis, Ulcerative — 1 open to participants now, 1 under way, none of them phase 3. Budesonide · Colitis, Ulcerative.

Enrollment
Largest of 10
510 · median 183
Started
2012
the only one that year
Phase 3
6 of 10
none open now
Registered
6th of 10
by date
Lead sponsor
5 of 10
Bausch Health Americas, Inc.

Among the 10 studies testing budesonide in Colitis, Ulcerative, this one has the largest enrollment, is the only one that started in 2012, is one of 6 in phase 3, and was the 6th registered.

Colitis, Ulcerative

1,857 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

1 of the 10 studies testing budesonide in Colitis, Ulcerative is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About budesonide

Budesonide: first FDA approval 1994 (RHINOCORT), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 305 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 135 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing budesonide in Colitis, Ulcerative, or all of them as a file.
02

Study summary

This study is to compare the efficacy and safety of budesonide MMX 9 mg versus placebo as add-on therapy to an existing oral 5-ASA regimen for the induction of remission in participants with active mild or moderate ulcerative colitis (UC).

Read the detailed description

Eligible participants will be randomized to 1 of the following 2 treatment arms:

  1. Budesonide MMX 9 mg (1 tablet)
  2. Placebo (tablet indistinguishable from budesonide MMX 9 mg tablet)

The assigned study drug will be taken as a single oral tablet each morning after breakfast. In addition to the study drug, all participants will continue their existing background oral 5-ASA regimen during the treatment period.

03

Conditions studied

  • Ulcerative Colitis

Browse trials for

Keywords

  • Ulcerative Colitis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18 to 75 years, inclusive.
  2. Established diagnosis of UC, based on clinical history, exclusion of infectious causes, and characteristic endoscopic and histologic findings.
  3. Active mild or moderate UC with an ulcerative colitis disease activity index (UCDAI) score ≥4 and ≤10, with a mucosal appearance score of ≥1, and physician's rating of disease activity of 1 or 2.
  4. Experiencing active UC (flare) despite a therapeutic dose of an oral 5-ASA (for example, mesalamine ≥2.4 g/day for ≥6 weeks prior to randomization, or equivalent). At screening, photographic evidence of active UC based on mucosal appearance must be obtained.
  5. Women of or men of must be willing to use an acceptable form of .
  6. Able to comprehend the full nature and purpose of the study, including possible risks and side effects, and also able to comply with all requirements of the study. Must be able to understand and voluntarily sign an prior to any study procedures.

Exclusion criteria

Exclusion Criteria:

  1. Limited distal proctitis (from anal verge to 15 centimeters [cm] above the pectineal line).
  2. Severe UC (UCDAI >10 or physician global assessment [PGA] >2), or non-active UC (UCDAI \<4).
  3. Infectious colitis or any recent history of infectious colitis (within 30 days of Screening).
  4. Active or carcinoma in situ within the last 5 years (treated non-melanoma skin cancers are not exclusionary).
  5. Active ulcer or bleeding disorder that may affect evaluation of blood in the stool.
  6. Evidence or history of toxic megacolon or bowel resection.
  7. Crohn's disease or indeterminate colitis.
  8. Known to budesonide or any ingredients of the budesonide MMX tablets.
  9. Active tuberculosis or other active systemic or local bacterial, fungal, or viral infection.
  10. Liver cirrhosis, evident hepatic or renal disease or insufficiency, or significant impairment of the biohumoral parameters (≥2.5* [ULN] for , aspartate aminotransferase, gamma-glutamyl transpeptidase, or ≥2*ULN for creatinine). Elevations in due to benign conditions such as Gilbert's syndrome are not exclusionary.
  11. Severe diseases in other organs or systems.
  12. Local or systemic complications or other pathological states requiring therapy with and/or agents.
  13. Type 1 diabetes.
  14. Glaucoma or with a family history of glaucoma in first-degree relatives.
  15. Known , , or (HIV), according to the local privacy policy.
  16. Severe anemia (\<9 g/deciliter [dL] ), leukopenia (\<2.5*10\^9 white blood cells [WBC]/liter [L]), or granulocytopenia (\<1.2*10\^9 cells/L).
  17. Participants with a history of pancolitis (disease that extends to the hepatic flexure or beyond) for ≥8 years or left-sided colitis (disease confined to the left colon [that is, distal to the splenic flexure]) ≥15 years who have not yet completed a surveillance colonoscopy for dysplasia/colorectal cancer screening within the past year.
  18. Prior budesonide MMX treatment.
  19. Use of oral corticosteroids including other budesonide formulations within the last 4 weeks prior to randomization.
  20. Use of any rectal 5-ASA or corticosteroid formulations within the last 2 weeks prior to randomization.
  21. Use of immunosuppressive agents within the last 8 weeks prior to randomization.
  22. Use of anti-tumor necrosis factor-alpha (TNFα) agents or other biologic therapies within the last 3 months prior to randomization.
  23. Participation in experimental therapeutic studies within 30 days of randomization (or within the last 3 months if in an anti-TNFα or biologic agent study). Note: participants who participated in observational-only studies (and who did not receive study therapy) are not excluded.
  24. Any other medical condition that, in the Principal Investigator's opinion, would make the administration of the study drug or study procedures hazardous to the participant or obscure the interpretation of adverse events (AEs) by the appropriate independent ethics committee/institutional review board.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
510 participants (actual)

Study arms

  • Experimental
    Budesonide MMX

    Participants will receive 1 oral tablet of budesonide MMX 9 mg for 56 days. Additionally, participants will continue to receive the same dose of their existing oral 5-ASA medication from their treating physician.

    Drug: Budesonide MMX® · Drug: 5-ASA

  • Placebo comparator
    Placebo

    Participants will receive 1 oral tablet of matching budesonide MMX placebo for 56 days. Additionally, participants will continue to receive the same dose of their existing oral 5-ASA medication from their treating physician.

    Drug: Placebo · Drug: 5-ASA

Interventions

  • DrugBudesonideStudies of BudesonideBudesonide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Oral tablet taken daily in the morning after breakfast.

    Also known as: Budesonide Multi-Matrix System

  • DrugPlacebo

    Matching budesonide MMX placebo oral tablet taken daily in the morning after breakfast.

  • DrugMesalamineStudies of MesalamineMesalamine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Acceptable oral 5-ASA medications to be received during the study include: * Asacol®, Asacol® HD, Lialda®, Pentasa® (generic: mesalamine), minimum daily dose ≥2.4 grams (g) * Azulfidine® (generic: sulfasalazine), minimum daily dose ≥4.0 g * Dipentum® (generic: olsalazine), minimum daily dose ≥2.0 g * Colazal®, Colazide® (generic: balsalazide), minimum daily dose ≥6.75 g

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Achieved Clinical Remission at Day 56

    Clinical remission defined as a score of 0 for rectal bleeding and 0 for stool frequency components from the Ulcerative Colitis Disease Activity Index (UCDAI). UCDAI is the sum (0 to 12) of 4 severity scores (0 to 3). Stool frequency and rectal bleeding were based on information recorded in daily participant diaries. The diary entries were averaged for rectal bleeding and stool frequency for 3 days prior to (and closest to) Day 56 with non-missing diary data, within 5 days prior to (and closest to) Day 56. The 5 days did not include any days of the flexible sigmoidoscopy (or colonoscopy) or the preparation for the flexible sigmoidoscopy (or colonoscopy). These averages were rounded to integer values. If either subscore could not be calculated because of missing data, the score for that UCDAI component was set to missing. Participants with insufficient data at Day 56 were excluded from the analysis. Participants who had clinical remission at Baseline were classified as non-responders.

    Time frame: Baseline up to Day 56

Secondary outcomes

  1. Number of Participants of Who Achieved Clinical Response at Day 56

    Clinical response defined as an improvement in UCDAI from Baseline of ≥3 points with a rectal bleeding score ≤1. UCDAI is the sum (0 to 12) of 4 severity scores (0 to 3). Rectal bleeding was based on information recorded in daily participant diaries. The diary entries were averaged for rectal bleeding for 3 days prior to (and closest to) Day 56 with non-missing diary data, within 5 days prior to (and closest to) Day 56. The 5 days did not include any days of the flexible sigmoidoscopy (or colonoscopy) or the preparation for the flexible sigmoidoscopy (or colonoscopy). These averages were rounded to integer values. If either subscore could not be calculated because of missing data, the score for that UCDAI component was set to missing. Participants with insufficient data at Day 56 were excluded from the analysis.

    Time frame: Baseline up to Day 56

  2. Number of Participants Who Achieved UCDAI Remission at Day 56

    UCDAI remission was defined as a total UCDAI score ≤1 with subscores of 0 for rectal bleeding, stool frequency, and mucosal appearance of the colon. UCDAI is the sum (0 to 12) of 4 severity scores (0 to 3). Stool frequency and rectal bleeding were based on information recorded in daily participant diaries and mucosal appearance was based on endoscopy results. The diary entries were averaged for rectal bleeding and stool frequency for 3 days prior to (and closest to) Day 56 with non-missing diary data, within 5 days prior to (and closest to) Day 56. The 5 days did not include any days of the flexible sigmoidoscopy (or colonoscopy) or the preparation for the flexible sigmoidoscopy (or colonoscopy). These averages were rounded to integer values. If the subscore could not be calculated because of missing data, the score for that UCDAI component was set to missing. Participants with insufficient data at Day 56 were excluded from the analysis.

    Time frame: Baseline up to Day 56

  3. Number of Participants Who Achieved Endoscopic Remission at Day 56

    Endoscopic remission was defined as a score of 0 in the mucosal appearance component subscore of the UCDAI at Day 56. UCDAI is the sum (0 to 12) of 4 severity scores (0 to 3). Mucosal appearance was based on endoscopy results. If the mucosal appearance subscore could not be calculated because of missing data, endoscopic remission was set to missing. Participants with insufficient data at Day 56 were excluded from the analysis.

    Time frame: Screening and Day 56

  4. Number of Participants Who Achieved Histologic Healing at Day 56

    Participants achieved histologic healing if histologic assessments of all biopsy specimens were graded as 0 (normal mucosa). If the score for ≥1 sample was missing, the overall score at that visit was set to missing. Participants with insufficient data at Day 56 were excluded from analysis.

    Time frame: Baseline and Day 56

  5. Number of Participants With Treatment Failure at Day 56

    Treatment failure was defined as an unchanged, worsened, or missing UCDAI score at Day 56. UCDAI is the sum (0 to 12) of 4 severity scores (0 to 3). Stool frequency and rectal bleeding was based on information recorded in daily participant diaries and mucosal appearance was based on endoscopy results. The diary entries were averaged for rectal bleeding and stool frequency for 3 days prior to (and closest to) Day 56 with non-missing diary data, within 5 days prior to (and closest to) Day 56. The 5 days did not include any days of the flexible sigmoidoscopy (or colonoscopy) or the preparation for the flexible sigmoidoscopy (or colonoscopy). These averages were rounded to integer values. If the subscore could not be calculated because of missing data, the score for that UCDAI component was set to missing. Participants with insufficient data at Day 56 were excluded from the analysis.

    Time frame: Baseline up to Day 56

  6. Change From Baseline in Inflammatory Bowel Disease-Quality of Life (IBD-QoL) Questionnaire Scores

    The IBD-QoL questionnaire was self-completed by the participant. The IBD-QoL is a disease-specific instrument to evaluate the quality of life of participants with UC. This 32-item questionnaire has 4 dimensions: bowel function, emotional function, systemic symptoms, and social function. The total score is presented, which ranges from 32 to 224, with higher scores indicating a better quality of life. The scores of participants in remission usually range from 170 to 190. If \>50% of the questionnaire answers for a particular dimension were missing, this dimension score was set to missing. The total score for the IBD-QoL was the sum of the domain scores, however, if any dimension score was missing, the total IBD-QoL score was set to missing.

    Time frame: Baseline, Days 14, 28, and 56

07

Results

Posted Sep 6, 2019

Participant flow

Participant flow — Overall Study
MilestoneBudesonide MMXPlacebo
Started255255
Safety population255255
Intent-to-treat population230228
Completed219238
Not completed3617
Withdrew: Lost to follow-up34
Withdrew: Lack of efficacy41
Withdrew: Protocol violation11
Withdrew: Adverse event129
Withdrew: Withdrawal by subject162

Outcome measures

PrimaryNumber of Participants Who Achieved Clinical Remission at Day 56

Clinical remission defined as a score of 0 for rectal bleeding and 0 for stool frequency components from the Ulcerative Colitis Disease Activity Index (UCDAI). UCDAI is the sum (0 to 12) of 4 severity scores (0 to 3). Stool frequency and rectal bleeding were based on information recorded in daily participant diaries. The diary entries were averaged for rectal bleeding and stool frequency for 3 days prior to (and closest to) Day 56 with non-missing diary data, within 5 days prior to (and closest to) Day 56. The 5 days did not include any days of the flexible sigmoidoscopy (or colonoscopy) or the preparation for the flexible sigmoidoscopy (or colonoscopy). These averages were rounded to integer values. If either subscore could not be calculated because of missing data, the score for that UCDAI component was set to missing. Participants with insufficient data at Day 56 were excluded from the analysis. Participants who had clinical remission at Baseline were classified as non-responders.

Time frame:
Baseline up to Day 56
Reported as:
Count of participants · Participants
Number of Participants Who Achieved Clinical Remission at Day 56
ParticipantsBudesonide MMXPlacebo
Number of Participants Who Achieved Clinical Remission at Day 565652
SecondaryNumber of Participants of Who Achieved Clinical Response at Day 56

Clinical response defined as an improvement in UCDAI from Baseline of ≥3 points with a rectal bleeding score ≤1. UCDAI is the sum (0 to 12) of 4 severity scores (0 to 3). Rectal bleeding was based on information recorded in daily participant diaries. The diary entries were averaged for rectal bleeding for 3 days prior to (and closest to) Day 56 with non-missing diary data, within 5 days prior to (and closest to) Day 56. The 5 days did not include any days of the flexible sigmoidoscopy (or colonoscopy) or the preparation for the flexible sigmoidoscopy (or colonoscopy). These averages were rounded to integer values. If either subscore could not be calculated because of missing data, the score for that UCDAI component was set to missing. Participants with insufficient data at Day 56 were excluded from the analysis.

Time frame:
Baseline up to Day 56
Reported as:
Count of participants · Participants
Number of Participants of Who Achieved Clinical Response at Day 56
ParticipantsBudesonide MMXPlacebo
Number of Participants of Who Achieved Clinical Response at Day 5610186
SecondaryNumber of Participants Who Achieved UCDAI Remission at Day 56

UCDAI remission was defined as a total UCDAI score ≤1 with subscores of 0 for rectal bleeding, stool frequency, and mucosal appearance of the colon. UCDAI is the sum (0 to 12) of 4 severity scores (0 to 3). Stool frequency and rectal bleeding were based on information recorded in daily participant diaries and mucosal appearance was based on endoscopy results. The diary entries were averaged for rectal bleeding and stool frequency for 3 days prior to (and closest to) Day 56 with non-missing diary data, within 5 days prior to (and closest to) Day 56. The 5 days did not include any days of the flexible sigmoidoscopy (or colonoscopy) or the preparation for the flexible sigmoidoscopy (or colonoscopy). These averages were rounded to integer values. If the subscore could not be calculated because of missing data, the score for that UCDAI component was set to missing. Participants with insufficient data at Day 56 were excluded from the analysis.

Time frame:
Baseline up to Day 56
Reported as:
Count of participants · Participants
Number of Participants Who Achieved UCDAI Remission at Day 56
ParticipantsBudesonide MMXPlacebo
Number of Participants Who Achieved UCDAI Remission at Day 563017
SecondaryNumber of Participants Who Achieved Endoscopic Remission at Day 56

Endoscopic remission was defined as a score of 0 in the mucosal appearance component subscore of the UCDAI at Day 56. UCDAI is the sum (0 to 12) of 4 severity scores (0 to 3). Mucosal appearance was based on endoscopy results. If the mucosal appearance subscore could not be calculated because of missing data, endoscopic remission was set to missing. Participants with insufficient data at Day 56 were excluded from the analysis.

Time frame:
Screening and Day 56
Reported as:
Count of participants · Participants
Number of Participants Who Achieved Endoscopic Remission at Day 56
ParticipantsBudesonide MMXPlacebo
Number of Participants Who Achieved Endoscopic Remission at Day 564628
SecondaryNumber of Participants Who Achieved Histologic Healing at Day 56

Participants achieved histologic healing if histologic assessments of all biopsy specimens were graded as 0 (normal mucosa). If the score for ≥1 sample was missing, the overall score at that visit was set to missing. Participants with insufficient data at Day 56 were excluded from analysis.

Time frame:
Baseline and Day 56
Reported as:
Count of participants · Participants
Number of Participants Who Achieved Histologic Healing at Day 56
ParticipantsBudesonide MMXPlacebo
Number of Participants Who Achieved Histologic Healing at Day 566240
SecondaryNumber of Participants With Treatment Failure at Day 56

Treatment failure was defined as an unchanged, worsened, or missing UCDAI score at Day 56. UCDAI is the sum (0 to 12) of 4 severity scores (0 to 3). Stool frequency and rectal bleeding was based on information recorded in daily participant diaries and mucosal appearance was based on endoscopy results. The diary entries were averaged for rectal bleeding and stool frequency for 3 days prior to (and closest to) Day 56 with non-missing diary data, within 5 days prior to (and closest to) Day 56. The 5 days did not include any days of the flexible sigmoidoscopy (or colonoscopy) or the preparation for the flexible sigmoidoscopy (or colonoscopy). These averages were rounded to integer values. If the subscore could not be calculated because of missing data, the score for that UCDAI component was set to missing. Participants with insufficient data at Day 56 were excluded from the analysis.

Time frame:
Baseline up to Day 56
Reported as:
Count of participants · Participants
Number of Participants With Treatment Failure at Day 56
ParticipantsBudesonide MMXPlacebo
Number of Participants With Treatment Failure at Day 564561
SecondaryChange From Baseline in Inflammatory Bowel Disease-Quality of Life (IBD-QoL) Questionnaire Scores

The IBD-QoL questionnaire was self-completed by the participant. The IBD-QoL is a disease-specific instrument to evaluate the quality of life of participants with UC. This 32-item questionnaire has 4 dimensions: bowel function, emotional function, systemic symptoms, and social function. The total score is presented, which ranges from 32 to 224, with higher scores indicating a better quality of life. The scores of participants in remission usually range from 170 to 190. If \>50% of the questionnaire answers for a particular dimension were missing, this dimension score was set to missing. The total score for the IBD-QoL was the sum of the domain scores, however, if any dimension score was missing, the total IBD-QoL score was set to missing.

Time frame:
Baseline, Days 14, 28, and 56
Reported as:
Mean · scores on a scale
Change From Baseline in Inflammatory Bowel Disease-Quality of Life (IBD-QoL) Questionnaire Scores
scores on a scaleBudesonide MMXPlacebo
Baseline132.8 ± 31.36134.1 ± 32.48
Change at Day 1424.4 ± 27.4521.3 ± 29.20
Change at Day 2831.8 ± 33.3825.7 ± 33.16
Change at Day 5631.1 ± 38.7331.7 ± 37.02

Adverse events

Collected over Baseline up to Day 85. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Budesonide MMX—10/255 (3.9%)14/255 (5.5%)
Placebo—2/255 (0.8%)14/255 (5.5%)
Most frequent serious events
Most frequent serious events
EventBudesonide MMXPlacebo
Colitis ulcerativeGastrointestinal disorders6/2551/255
Pancreatitis activeGastrointestinal disorders1/2550/255
AnemiaBlood and lymphatic system disorders1/2550/255
BronchitisInfections and infestations1/2550/255
HypokalemiaMetabolism and nutrition disorders1/2550/255
Type 2 diabetes mellitusMetabolism and nutrition disorders0/2551/255
Most frequent other events
Most frequent other events
EventBudesonide MMXPlacebo
Colitis ulcerativeGastrointestinal disorders11/2559/255
AcneSkin and subcutaneous tissue disorders3/2555/255

Baseline characteristics

All randomized participants who received at least 1 dose of study drug (Safety Population).

Age, Continuous
Age, Continuous(years)Budesonide MMXPlaceboTotal
Mean44.5 ± 13.8644.9 ± 13.4444.7 ± 13.64
Sex: Female, Male
Sex: Female, Male(Participants)Budesonide MMXPlaceboTotal
Female122108230
Male133147280
08

Study locations

114 sites
  • Santarus Clinical Investigational Site 1043
    Anaheim, California 92801, United States
  • Santarus Clinical Investigational Site 1071
    Lakewood, California 90712, United States
  • Santarus Clinical Investigational Site 1003
    San Diego, California 92114, United States
  • Santarus Clinical Investigational Site 1063
    Littleton, Colorado 80120, United States
  • Santarus Clinical Investigational Site 1028
    Bristol, Connecticut 06010, United States
  • Santarus Clinical Investigational Site 1035
    Boynton Beach, Florida 33426, United States
  • Santarus Clinical Investigational Site 1045
    Jacksonville, Florida 32256, United States
  • Santarus Clinical Investigational Site 1001
    Largo, Florida 33777, United States
  • Santarus Clinical Investigational Site 1024
    Maitland, Florida 32751, United States
  • Santarus Clinical Investigational Site 1029
    Port Orange, Florida 32127, United States
  • Santarus Clinical Investigational Site 1010
    Winter Park, Florida 32789, United States
  • Santarus Clinical Investigational Site 1002
    Zephyrhills, Florida 33613, United States
  • Santarus Clinical Investigational Site 1050
    Decatur, Georgia 30033, United States
  • Santarus Clinical Investigational Site 1075
    Chicago, Illinois 60637, United States
  • Santarus Clinical Investigational Site 1065
    Oak Lawn, Illinois 60453, United States
  • Santarus Clinical Investigational Site 1058
    Indianapolis, Indiana 46202, United States
  • Santarus Clinical Investigational Site 1032
    Shreveport, Louisiana 71103, United States
  • Santarus Clinical Investigational Site 1044
    Annapolis, Maryland 21401, United States
  • Santarus Clinical Investigational Site 1016
    Chesterfield, Michigan 48047, United States
  • Santarus Clinical Investigational Site 1081
    Novi, Michigan 48377, United States
  • Santarus Clinical Investigational Site 1015
    Wyoming, Michigan 49159, United States
  • Santarus Clinical Investigational Site 1068
    Ypsilanti, Michigan 48197, United States
  • Santarus Clinical Investigational Site 1074
    Rochester, Minnesota 55905, United States
  • Santarus Clinical Investigational Site 1061
    Lebanon, New Hampshire 03756, United States
  • Santarus Clinical Investigational Site 1021
    Cheektowaga, New York 14225, United States
  • Santarus Clinical Investigational Site 1072
    Great Neck, New York 11023, United States
  • Santarus Clinical Investigational Site 1031
    New York, New York 10028, United States
  • Santarus Clinical Investigational Site 1073
    Wilmington, North Carolina 28403, United States
  • Santarus Clinical Investigational Site 1080
    Cincinnati, Ohio 45267, United States
  • Santarus Clinical Investigational Site 1078
    Cleveland, Ohio 44195, United States
  • Santarus Clinical Investigational Site 1082
    Dayton, Ohio 45415, United States
  • Santarus Clinical Investigational Site 1064
    Lancaster, Pennsylvania 17604, United States
  • Santarus Clinical Investigational Site 1006
    Sayre, Pennsylvania 18840, United States
  • Santarus Clinical Investigational Site 1059
    Austin, Texas 78705, United States
  • Santarus Clinical Investigational Site 1039
    Houston, Texas 77030, United States
  • Santarus Clinical Investigational Site 1005
    Pasadena, Texas 77505, United States
  • Santarus Clinical Investigational Site 1014
    Lancaster, Utah 84341, United States
  • Santarus Clinical Investigational Site 1038
    Chesapeake, Virginia 23320, United States
  • Santarus Clinical Investigational Site 1025
    Christiansburg, Virginia 24073, United States
  • Santarus Clinical Investigational Site 4003
    Pleven, Bulgaria
  • Santarus Clinical Investigational Site 4004
    Plovdiv, Bulgaria
  • Santarus Clinical Investigational Site 4009
    Plovdiv, Bulgaria
  • Santarus Clinical Investigational Site 4008
    Ruse, Bulgaria
  • Santarus Clinical Investigational Site 4001
    Sofia, Bulgaria
  • Santarus Clinical Investigational Site 4002
    Sofia, Bulgaria
  • Santarus Clinical Investigational Site 4005
    Sofia, Bulgaria
  • Santarus Clinical Investigational Site 4007
    Sofia, Bulgaria
  • Santarus Clinical Investigational Site 4010
    Sofia, Bulgaria
  • Santarus Clinical Investigational Site 4011
    Sofia, Bulgaria
  • Santarus Clinical Investigational Site 2003
    Winnipeg, Manitoba R3A1R9, Canada
  • Santarus Clinical Investigational Site 2008
    Halifax, Nova Scotia, Canada
  • Santarus Clinical Investigational Site 2004
    London, Ontario, Canada
  • Santarus Clinical Investigational Site 2010
    Ottawa, Ontario, Canada
  • Santarus Clinical Investigational Site 2002
    Vaughan, Ontario L4L4Y7, Canada
  • Santarus Clinical Investigational Site 2009
    Montreal, Quebec, Canada
  • Santarus Clinical Investigational Site 2001
    Sherbrooke, Quebec J1G2E8, Canada
  • Santarus Clinical Investigational Site 2007
    Calgary, Canada
  • Santarus Clinical Investigational Site 2005
    London, Canada
  • Santarus Clinical Investigational Site 2006
    Quebec, Canada
  • Santarus Clinical Investigational Site 3001
    Hradec Kralove, Czechia
  • Santarus Clinical Investigational Site 3006
    Hradec Kralove, Czechia
  • Santarus Clinical Investigational Site 3005
    Labem, Czechia
  • Santarus Clinical Investigational Site 3003
    Olomouc, Czechia
  • Santarus Clinical Investigational Site 3009
    Prague, Czechia
  • Santarus Clinical Investigational Site 3004
    Praha, Czechia
  • Santarus Clinical Investigational Site 3007
    Praha, Czechia
  • Santarus Clinical Investigational Site 3002
    Tabor, Czechia
  • Santarus Clinical Investigational Site 3010
    Usti nad Orlici, Czechia
  • Santarus Clinical Investigational Site 3011
    Valasske Mezirici, Czechia
  • Santarus Clinical Investigational Site 8001
    Tallinn, Estonia
  • Santarus Clinical Investigational Site 5010
    Bekescsaba, Hungary
  • Santarus Clinical Investigational Site 5008
    Budapest, Hungary
  • Santarus Clinical Investigational Site 5009
    Budapest, Hungary
  • Santarus Clinical Investigational Site 5001
    Debrecen, Hungary
  • Santarus Clinical Investigational Site 5003
    Gyula, Hungary
  • Santarus Clinical Investigational Site 5004
    Kaposvar, Hungary
  • Santarus Clinical Investigational Site 5002
    Miskolc, Hungary
  • Santarus Clinical Investigational Site 5006
    Mosonmagyarovar, Hungary
  • Santarus Clinical Investigational Site 5011
    Pecs, Hungary
  • Santarus Clinical Investigational Site 5005
    Szeged, Hungary
  • Santarus Clinical Investigational Site 5007
    Vac, Hungary
  • Santarus Clinical Investigational Site 8101
    Riga, Latvia
  • Santarus Clinical Investigational Site 8102
    Riga, Latvia
  • Santarus Clinical Investigational Site 8103
    Riga, Latvia
  • Santarus Clinical Investigational Site 8202
    Kaunas, Lithuania
  • Santarus Clinical Investigational Site 8201
    Vilnius, Lithuania
  • Santarus Clinical Investigational Site 8203
    Vilnius, Lithuania
  • Santarus Clinical Investigational Site 6003
    Elblag, Poland
  • Santarus Clinical Investigational Site 6001
    Krakow, Poland
  • Santarus Clinical Investigational Site 6002
    Sopot, Poland
  • Santarus Clinical Investigational Site 6006
    Szczecin, Poland
  • Santarus Clinical Investigational Site 6004
    Warszawa, Poland
  • Santarus Clinical Investigational Site 6008
    Warszawa, Poland
  • Santarus Clinical Investigational Site 6005
    Warszawy, Poland
  • Santarus Clinical Investigational Site 9016
    Lipetsk, Russian Federation
  • Santarus Clinical Investigational Site 9005
    Moscow, Russian Federation
  • Santarus Clinical Investigational Site 9010
    Moscow, Russian Federation
  • Santarus Clinical Investigational Site 9004
    Nizhny Novgorod, Russian Federation
  • Santarus Clinical Investigational Site 9003
    Ryazan, Russian Federation
  • Santarus Clinical Investigational Site 9008
    Saint Petersburg, Russian Federation

Showing the first 100 of 114 sites across 11 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Rubin DT, Cohen RD, Sandborn WJ, Lichtenstein GR, Axler J, Riddell RH, Zhu C, Barrett AC, Bortey E, Forbes WP. Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial. J Crohns Colitis. 2017 Jul 1;11(7):785-791. doi: 10.1093/ecco-jcc/jjx032. Erratum In: J Crohns Colitis. 2017 Dec 4;11(12):1510. doi: 10.1093/ecco-jcc/jjx052. PubMed 28333362 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2012 to primary completion in Oct 2013, 20 months.

Results were first posted in Sep 2019, 5 years 11 months after primary completion.

Of 87 industry-sponsored phase 3 interventional studies under Colitis, Ulcerative, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 70. This study's 20 months is below that.

Counting every sponsor, half of 101 studies reached it within 48 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2011
First posted
Feb 14, 2012
StartActual
Jan 27, 2012
Primary completionActual
Oct 2, 2013
CompletionActual
Oct 2, 2013
Results first posted
Sep 6, 2019
Last update
Sep 6, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 6, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01532648
Responsible party
Sponsor
First posted
Feb 14, 2012
Start date
Jan 27, 2012
Primary completion
Oct 2, 2013
Completion
Oct 2, 2013
Results posted
Sep 6, 2019
Last update
Sep 6, 2019

Study contacts

Lindsey Mathew
study director · Bausch Health Companies

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Budesonide

Start the discussion